AI-generated · Based on company filings and platform data · Not investment advice
Gilead (GILD) Q3 2026 Earnings Brief: Revenue $8.30B, +6.8% YoY
Released Oct 29, 2026 (ET)
Quarter: Q3 2026, period ended 2026-09-30; released 2026-10-29 (ET).
In one line: Gilead's revenue in the third quarter of 2026 was US$8.30 billion, with adjusted earnings per share of US$2.55, exceeding analysts' consensus expectations by 16.2%.
Key numbers
| Metric | This quarter | Note |
|---|---|---|
| Revenue | $8.30B | YoY +6.8% |
| Adj. EPS vs consensus | $2.55 vs $2.19 | Beat (+16.2%) |
| GAAP diluted EPS | $1.94 | Different basis from consensus |
| Net margin | 29.3% | Net income $2.43B |
| Next-quarter EPS consensus | $1.09 | 20 analysts; revenue consensus $8.33B |
Three things to know
1. Revenue increased 6.8% year-on-year
Revenue for the quarter was US$8.30 billion, an increase of 6.8% from US$7.80 billion in the same period last year, reflecting the continued improvement in sales performance of core products. The data source is the quarterly revenue and year-on-year growth disclosed in the financial report.
2. Adjusted EPS exceeded expectations by 16.2%
Adjusted earnings per share were $2.55, 16.2% higher than analysts’ consensus estimate of $2.19. This comparison is based on the same caliber (non-GAAP) consensus data.
3. Net profit margin reached 29.3%
Net profit for the quarter was US$2.43 billion, with a net profit margin of 29.3%, indicating that profitability remained stable. This data comes from the calculation of the ratio of net income to revenue in the financial report.
Market reaction
Results were released on 2026-10-29 (ET). From the last pre-report close (2026-10-28, $159.20) to the close of the first session after the report (2026-10-30, $170.68), the stock moved +7.21%. The report-day close was $165.61; the next session closed +3.06% from it (for after-hours releases, this leg better reflects the reaction to the report).
What to watch next
- Pay attention to the fourth quarter financial report date of 2026 (2027-02-09) and changes in the consensus profit forecast for the next quarter.
- Pay attention to the future capital expenditure plans and R&D investment directions mentioned by management in the financial report.
- Track the progress of the impact of the U.S. Inflation Reduction Act on medical insurance pricing policies, especially the determination of the maximum fair price of Biktarvy.
- Next report date (platform calendar): 2027-02-09
Sources
- Financials: fundamentals-svc (EDGAR filings, analyst consensus)
- Prices: fundamentals-svc /v1/candles-ondemand
- MD&A source: 10-Q (filed 2026-10-30)
- Company press release (8-K): SEC EDGAR